Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO
Executive Summary
Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.
You may also be interested in...
Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Ascletis was the first with a new listing under new Hong Kong rules, but BeiGene also sold shares on the HKEX; the companies raised more than $1bn combined. Also, TherapeuticsMD sold stock in the US to commercialize Imvexxy, Curon raised the latest $150m VC mega-round, and NewLink cut jobs in R&D refocus.
Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development
Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.
Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.